A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Alpelisib BYL719 in Combination with Nab-Paclitaxel in Patients with Advanced Triple Negative Breast Cancer with Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha PIK3CA Mutation or Phosphatase and Tensin Homolog Protein PTEN Loss Without PIK3CA Mutation

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04251533

Study #:
STUDY00145707

Start Date:
Dec 21, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04251533

View Complete Trial Details & Eligibility at ClinicalTrials.gov